Nov 7, 2019

Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis

AIDS
Tammy MeyersIMPAACT P1101 Team

Abstract

Drug-drug interactions limit current antiretroviral treatment options for HIV-infected children with tuberculosis (TB). Rifampicin (RIF) induces UDP-glucuronosyltransferase activity, accelerating the clearance of raltegravir (RAL). We sought to establish an optimal and well tolerated dose of RAL when administered with RIF to HIV and TB co-infected children. P1101 is a phase I/II open-label dose-finding study of RAL with RIF for children 2 to less than 12 years of age beginning treatment for HIV and active TB. Four sites in South Africa. Chewable RAL was given at 12 mg/kg per dose twice daily (twice the usual pediatric dose) with two nucleoside reverse transcriptase inhibitors. Intensive RAL pharmacokinetic sampling was conducted 5 to 8 days after antiretroviral therapy was initiated; a fourth antiretroviral agent was then added. Children were recruited into two age-defined groups: cohort 1 (2 to <6 years old) and cohort 2 (6 to <12 years old). Pharmacological targets [geometric mean (GM) AUC12 h of 14-45 μmol/l h and GM C12 h ≥75 nmol/l) were reached in both cohort 1 (28.8 μmol/l h and 229 nmol/l) and cohort 2 (38.8 μmol/l h and 228 nmol/l). The RAL-based ART was well tolerated by most participants: one participant discontinued...Continue Reading

  • References
  • Citations1

References

  • We're still populating references for this paper, please check back later.
  • References
  • Citations1

Citations

Mentioned in this Paper

Study
Treatment Protocols
Human immunodeficiency virus 1 RNA
Tuberculosis
Anti-Retroviral Agents
Hepatitis
Glucuronosyltransferase
Coinfection
Antiretroviral Therapy
HIV Infections

Related Feeds

AIDS Malignancies

HIV infection increases the risk of non-communicable diseases common in the aged, including cardiovascular disease, neurocognitive decline, non-aids malignancies, osteoporosis, and frailty. Discover the latest research in AIDS malignancies.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Anne-Marie TaburetJean-Michel Molina
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Caroline BarauAgence Nationale de Recherche sur le Sida et les hépatites (ANRS) 148 Study Group
Molecular and Cellular Biology
R M WolthuisJ L Bos
© 2020 Meta ULC. All rights reserved